Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Relmada Therapeutics (RLMD) Depreciation & Amortization (CF) (2016 - 2021)

Relmada Therapeutics has reported Depreciation & Amortization (CF) over the past 2 years, most recently at $150.0 for Q1 2014.

Quarterly Depreciation & Amortization (CF) changed N/A to $150.0 in Q1 2014 from the year-ago period, while the trailing twelve-month figure was $450.0 through Feb 2014, changed N/A year-over-year, with the annual reading at $1258.0 for FY2021, 66.47% down from the prior year.
Depreciation & Amortization (CF) was $150.0 for Q1 2014 at Relmada Therapeutics, roughly flat from $150.0 in the prior quarter.
Over five years, Depreciation & Amortization (CF) peaked at $150.0 in Q3 2013 and troughed at $150.0 in Q3 2013.